Olokizumab, a new drug for managing rheumatoid arthritis
Despite the recent therapeutic advances, nearly 25% of patients are refractory to the treatment regimens. The findings of an international multi-centre study led by MedUni …
big pharma
Despite the recent therapeutic advances, nearly 25% of patients are refractory to the treatment regimens. The findings of an international multi-centre study led by MedUni …